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Abstract
Background: Conservative treatment of uncomplicated or mild diverticulitis usually includes antibiotic therapy. It is,
however, uncertain whether patients with acute diverticulitis indeed benefit from antibiotics. In most guidelines
issued by professional organizations antibiotics are considered mandatory in the treatment of mild diverticulitis.
This advice lacks evidence and is merely based on experts’ opinion. Adverse effects of the use of antibiotics are
well known, including allergic reactions, development of bacterial resistance to antibiotics and other side-effects.
Methods: A randomized multicenter pragmatic clinical trial comparing two treatment strategies for uncomplicated
acute diverticulitis. I) A conservative strategy with antibiotics: hospital admission, supportive measures and at least
48 hours of intravenous antibiotics which subsequently are switched to oral, if tolerated (for a total duration of
antibiotic treatment of 10 days). II) A liberal strategy without antibiotics: admission only if needed on clinical
grounds, supportive measures only. Patients are eligible for inclusion if they have a diagnosis of acute
uncomplicated diverticulitis as demonstrated by radiological imaging. Only patients with stages 1a and 1b
according to Hinchey’s classification or “mild” diverticulitis according to the Ambrosetti criteria are included. The
primary endpoint is time-to-full recovery within a 6-month follow-up period. Full recovery is defined as being
discharged from the hospital, with a return to pre-illness activities, and VAS score below 4 without the use of daily
pain medication. Secondary endpoints are proportion of patients who develop complicated diverticulitis requiring
surgery or non-surgical intervention, morbidity, costs, health-related quality of life, readmission rate and acute
diverticulitis recurrence rate. In a non-inferiority design 264 patients are needed in each study arm to detect a
difference in time-to-full recovery of 5 days or more with a power of 85% and a confidence level of 95%. With an
estimated one percent of patients lost to follow up, a total of 533 patients will be included.
Conclusion: A clinically relevant difference of more than 5 days in time-to-full recovery between the two
treatment strategies is not expected. The liberal strategy without antibiotics and without the strict requirement for
hospital admission is anticipated to be more a more cost-effective approach.
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Background
Prevalence of diverticular disease increases with age,
from less than 10% in people younger than age 40 to
50-66% in octogenarians, with similar frequency in men
and women. Approximately three quarters of patients
with diverticulosis remain asymptomatic throughout
their lifetime. Asymptomatic disease is often an inciden-
tal finding during imaging or endoscopy for suspicion of
colonic disorders. Of the 25% of patients who develop
symptomatic diverticular disease, approximately three
quarters develop diverticulitis [1,2]. Of all patients with
diverticulitis, 75% have mild acute disease only and 25%
develop complicated disease [3]. All and all about 5% of
patients with diverticulosis will undergo an episode of
complicated diverticulitis.
The cause of colonic diverticular disease has not yet
been conclusively established. Epidemiologic studies
have demonstrated associations between diverticulosis
and diets that are low in dietary fiber and high in
refined carbohydrates. Low intake of dietary fiber results
in less bulky stools retaining less water and altering gas-
trointestinal transit time. These factors could increase
intracolonic pressure (development of pressure zones
that create diverticula alongside the vasa recta), and
make evacuation of colonic contents more difficult [4].
Other factors that have been associated with an
increased risk of diverticular disease include physical
inactivity, constipation, obesity, smoking, and treatment
with non-steroidal anti-inflammatory drugs [5,6].
Although much has been learned about the develop-
ment of diverticula, less is known about the pathogen-
esis of diverticular inflammation. As discussed earlier, a
minority of patients with diverticulosis will develop
symptomatic disease. Initial theories of diverticulitis
focused on ideas about the pathogenesis of appendicitis;
a diverticulum lumen becomes obstructed by a faecolith
leading to increased intradiverticular pressure and even-
tually causing inflammation. Interest has been generated
in the role of altered peridiverticular colonic flora and
low-grade chronic inflammation leading to periods of
symptomatic disease, similar to periods of exacerbation
and remission in inflammatory bowel disease [7].
The classical clinical presentation of diverticulitis in the
western world includes left lower quadrant abdominal
pain, tenderness, low-grade fever and leucocytosis. How-
ever, clinical features can be quite variable. Leucocytosis
may only be present in 45-65% of the patients, and low-
grade fever may be present in only 21% [8].
For a reliable diagnosis additional imaging is usually
necessary. Computed tomography (CT) is recommended
as initial radiological examination. Positive findings in
ultrasound (US) are equally accurate in the diagnosis of
diverticulitis. However CT has an advantage in excluding
alternative diagnoses and visualising complications of
acute diverticulitis needing intervention. For both US and
CT, sensitivity is as high as 90%, with a specificity of up to
99% for CT [9].
The severity of diverticulitis is often graded with the
use of modified Hinchey’s criteria, based on CT imaging
and on preoperative findings [10,11]. The Ambrosetti’s
criteria is based only on CT imaging, classifying in
“mild” and “severe” diverticulitis. This classification sys-
tem does not take into account the effects of coexisting
conditions on disease severity or outcome [12]. (Table
1) Stage II disease is related to a large (> 5 cm) collec-
tion of pus, which is at distance (in the pelvis or the
abdomen) of the sigmoid colon [10]. Stage II usually
requires percutaneous drainage, while stages III and IV
diverticulitis usually request surgery.
Conservative treatment of mild diverticulitis usually
includes careful observation, restriction of oral intake,
administration of intravenous fluids, and most patients
receive antibiotic therapy. The majority of patients with
mild diverticulitis improve with these conservative mea-
sures. Less than 10% need percutaneous or operative treat-
ment for disease progression and/or complications [13,14].
It is, however, uncertain whether patients with acute
diverticulitis benefit from antibiotics, since evidence
from prospective studies or randomized trials is lacking.
In a recent review antibiotics are considered mandatory
in the treatment of mild diverticulitis [15]. This advice
lacks evidence and is based on experts’ opinion only.
Anaerobes are commonly isolated organisms in acute
diverticulitis. Gram-negative aerobes, especially Escheri-
chia coli, and facultative gram-positive bacteria, such as
streptococci, are often cultured as well [16]. Therefore,
broad-spectrum antibiotics are advised. Which antibiotic
regimen should be used in diverticulitis is unclear
[17,18]. There is scarse evidence that oral antibiotics are
as effective as intravenous antibiotics [19].
Only one study has investigated the use of antibiotics
in the treatment of acute uncomplicated diverticulitis. In
a retrospective study by Hjern et al [20], there was no
significant benefit from antibiotics in the treatment of
mild diverticulitis. However, this study was hampered by
selection bias due to its retrospective design and small
patient groups.
Moreover, there is major discrepancy in the use of
antibiotics between countries in Northwest Europe and
other countries, including the United States and United
Kingdom. In the Netherlands and Scandinavian coun-
tries antibiotic use for this disease is less common com-
pared to these other countries, where antibiotics are
considered mandatory. A Dutch survey showed that
many gastro-enterologists prescribed antibiotics in the
treatment of acute diverticulitis, but only a minority of
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Dutch surgeons did so [21]. In contrast, all UK surgeons
responding to a survey prescribed antibiotics in the
initial treatment of diverticulitis and 43% of them even
for 7 days after hospital discharge [22].
Six professional organisations have issued formal
guidelines concerning the use of antibiotics in uncom-
plicated diverticulitis. Five of these guidelines advice the
use of antibiotics. (Table 2) [23-28]. Patients should
start with intravenous antibiotics and after improvement
within 2-4 days, oral antibiotics are continued to com-
plete a 7-10 days treatment regimen. In the Netherlands,
the Dutch Antibiotic Policy Committee considers anti-
biotics not primarily indicated in the treatment of
uncomplicated diverticulitis [28].
Adverse effects of antibiotics are well known, such as
allergic reactions and development of antibiotic resis-
tance of bacterial species. The frequency of toxicoder-
mia is 7-8% with the use amoxicillin, allergy reactions
are accounted for in 1% of the patients, and the inci-
dence of anaphylactic shock is 0,01-0,04% with the use
of penicillin. Therefore, efforts are made to minimize
the use of antibiotics in various fields in clinical medi-
cine [29].
The lack of evidence for its use necessitates a scientific
judgement of the role of antibiotics in the treatment of
uncomplicated diverticulitis. Therefore, we initiated a
randomized multicenter trial to investigate the effect of
antibiotics on disease course in patients with mild acute
diverticulitis.
Methods/Design
Objective
The main goal of the present study is to establish
whether antibiotics are necessary in the primary treat-
ment of acute mild diverticulitis, and whether a more
liberal strategy without initial antibiotics is more cost-
effective with respect to time-to-full recovery.
In daily practice there is an ongoing discussion about
the relative benefits and disadvantages of a more conser-
vative treatment strategy embracing the use of intrave-
nous antibiotics. This strategy needs hospital admission
and is, at least at the start, an in-hospital treatment regi-
men. A more liberal strategy, without antibiotics and
without the strict requirement of hospital admission,
may lead to a shorter hospital stay and reduced costs
without compromising outcome.
Table 1 Hinchey classification and modified Hinchey classification of acute diverticulitis [10,12]
Hinchey Modified Hinchey
0 Mild clinical diverticulitis
I Pericolic abscess or phlegmon 1a Colonic wall thickening/Confined pericoloc inflammation
Ib Confined small (< 5 cm) pericolic abscess
II Pelvic, intraabdominal, or retroperitoneal abscess II Pelvic, distant intraabdominal, or retroperitoneal abscess
III Generalized purulent peritonitis III Generalized purulent peritonitis
IV Generalized fecal peritonitis IV Fecal peritonitis
Table 2 Published guidelines and practise parameters
Organization Year Antibiotics
Recommended
Original
research
cited
Which
antibiotics
Original
research
cited
Route of administering Original
research
cited
American College of
Gastroenterology[23]
1999 Yes None Covering both Gram
negative and
anaerobes
Kellum [15] Oral or intravenous,
depending on clinical
status
None
European Association for
Endoscopic Surgery[25]
1999 Yes None Ciprofloxacin
And Metronidazol
None Oral or intravenous,
depending on clinical
status
None
American Society of Colon
and Rectal Surgeons[24]
2006 Yes None Covering both Gram
negative and
anaerobes
Kellum [15] Oral or intravenous,
depending on clinical
status
None
Society of Surgery of the
Alimentary Tract[26]
2007 Yes None Broad spectrum
antibiotics
None Oral or intravenous,
depending on clinical
status
None
World Gastroenterology
Organization[27]
2007 Yes None Covering both Gram
negative and
anaerobes
None Oral or intravenous,
depending on clinical
status
None
SWAB[28] 2009 No, not
primarily
None Broad spectrum
antibiotics
None Oral or intravenous,
depending on clinical
status
None
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Our hypothesis is that in uncomplicated (mild) acute
diverticulitis, a liberal strategy treatment without anti-
biotics is a more cost-effective approach than conserva-
tive treatment strategy with hospital admission and
antibiotics, outcome is measured by time-to-full recov-
ery as primary outcome and diverticulitis-associated
complication rates and patient well-being as secondary
outcome.
Study population
Inclusion criteria:
1. Only left-sided and primary (first attack) mild acute
diverticulitis.
2. Diagnosis of diverticulitis by US and conditional
CT. Diverticulitis-positive US findings are sufficiently
accurate compared to CT findings [9]. In diverticulitis-
negative US findings in clinically suspected patients,
immediate i.v. contrast-enhanced CT is mandatory for
confirmation of diverticulitis and exclusion of other
pathology.
3) Staging of diverticulitis by CT. CT is needed for all
patients for Hinchey/Ambrosetti classification (which is
a CT-based classification system). In diverticulitis-posi-
tive US findings CT has to be performed within 24
hours. Staging diverticulitis is defined according the
modified Hinchey/Ambrosetti staging. Only modified
Hinchey stages 1a and 1b (1a Colonic wall thickening/
Confined pericolic inflammation, 1b Confined small
pericolic abscess) and Ambrosetti’s “mild” diverticulitis
stage are included. Figure 1 depicts a flow chart, show-
ing the inclusion criteria and the steps after inclusion
[10-12].
4. Informed consent.
Exclusion criteria are summarized in Table 3.
Study outline
Patients will be randomly allocated to one of the follow-
ing two treatment strategies: Conservative strategy
including immediate antibiotic treatment or liberal strat-
egy without antibiotics (supportive measures only).
(Table 4).
In the conservative strategy, the use of antibiotics will
be intravenously for at least 48 hours after which route
of administration can be switched to orally if tolerated.
Hospital admission in the liberal strategy is needed for
patients with nausea and vomiting, in need of intrave-
nous fluids or for patients with excessive pain not prop-
erly reacting to oral pain medication.
The interval between start of symptoms of the patient
and administration of antibiotics will be registered. Also
the period after inclusion and the actual first adminis-
tration of antibiotics will be registered.
In both strategies CT is repeated in case of clinical
deterioration. For patients in the liberal strategy
treatment arm, clinical deterioration and/or proven sub-
sequent complicated diverticulitis and/or other infec-
tious foci (e.g., pneumonia, infections) may dictate start
of antibiotic treatment, instigated by the treating physi-
cian. Criteria to start antibiotics in the liberal arm are
temperature > 39°C, positive blood cultures and clinical
suspicion of bacteraemia (i.e. sepsis). Criteria for sepsis
are set by the American College of Chest Physicians and
the Society of Critical Care Medicine. Two or more
symptoms are required: Body temperature < 36°C or >
38°C, heart rate higher than 100 beats a minute, respira-
tory rate higher than 20 breaths a minute and white
blood cell count < 4 × 109 or > 12 × 109 cells/L [31].
Also another infectious focus (e.g., pneumonia, urinary
tract infections) may dictate start of antibiotic treatment,
instigated by the treating physician.
The following discharge criteria are applied in both
strategies: normal diet (defined by tolerating solid food
and more than 1L of fluid orally), temperature < 38.0°C,
VAS (Visual Analoge Score) pain score < 4 (with para-
cetamol only), self support as compared to the pre-ill-
ness level, and acceptance by the patient.
All outpatients will daily monitor and register their
body temperature. Written and oral instructions at dis-
charge are given, and relevant telephone numbers and
contact information will be provided. In case of fever
above 38˚C, progression of pain above a VAS of 4 or
other clinical signs of deterioration, patients can contact
the hospital or emergency department immediately.
Antibiotics
For the choice and duration of antibiotics the practice
guidelines of the Dutch Antibiotic Policy Committee
[28] and the American Society of Colon and Rectal Sur-
geons [30] are followed. In both guidelines, a minimum
of 7-14 days of broad-spectrum antibiotics is advised. In
the present study amoxicillin-clavulanic acid is chosen
as broad-spectrum antibiotic; duration of antibiotic
treatment is 10 days. The dosage scheme for the study
drug is 1200 mg i.v. 4 times daily with subsequent oral
administration of 625 mg 3 times daily. In case of
allergy (known or newly diagnosed), a switch will be
made to the combination of ciprofloxacine and metroni-
dazole; ciprofloxacine 2 times a day 400 mg i.v. and
metronidazol 3 times daily 500 mg, with oral doses of
ciprofloxacine being 500 mg 2 times a day and of
metronidazol 3 times a day 500 mg.
Endpoints
The primary endpoint is time-to-full recovery within a
follow-up period of 6 months. Full recovery is defined
by the following criteria: discharged from the hospital
(out-patient), normal diet (defined by tolerating solid
food and more than 1L of fluid orally), temperature
< 38.0°C, and VAS pain score < 4, no use of daily pain
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medication or back to pre-illness pain medication use,
and resuming to pre-illness working activities; as
assessed by questionnaires and out-patient clinic visits.
The secondary endpoints are: proportion of patients
who develop complicated diverticulitis require surgery
or non-surgical intervention; number of days outside the
hospital in a 6 months period; direct and indirect medi-
cal costs at 6 months follow-up; occurrence of compli-
cated diverticulitis defined as abscess, perforation,
stricture and/or fistula; predefined side-effects of initial
antibiotic treatment (e.g. antibiotic resistance/sensitivity
pattern, allergy); morbidity (e.g. pneumonia, myocardial
Figure 1 Study flow chart.
Table 3 Exclusion criteria
1. Previous radiological (US and/or CT) proven episode of diverticulitis;
2. US and/or CT suspicion of colonic cancer
3. Inflammatory bowel disease (ulcerative colitis, Crohn’s disease);
4. Hinchey stages 2, 3 and 4 or “severe” diverticulitis according to the Ambrosetti criteria, which require surgical or percutaneous treatment;
5. Other disease with expected survival of less than 6 months;
6. Contraindication for the use of the study medication (e.g. patients with advanced renal failure or allergy to antibiotics used in this study);
7. Pregnancy;
8. ASA (American Society of Anesthesiologists) classification > III;
9. Immunocompromised patient; (i.e., haematological malignancies, AIDS patients with low CD4+ counts, transplantation, chemotherapy,
splenectomy, long-term corticosteroid use and genetic disorders such as severe combined immunodeficiency.
10. Clinical suspicion of bacteraemia (i.e. sepsis);
11. The ability of reading/understanding and filling in the questionnaires.
12. Antibiotic use in the 4 weeks prior to inclusion
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infarction, urinary tract infection); mortality; readmis-
sion rate within 6 months and acute diverticulitis recur-
rence rates at 12 and 24 months follow-up. Changes in
health status and valuation over time will be measured
using generic and disease specific quality of life ques-
tionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and the
Gastro-Intestinal Quality of Life Index (Giqli)) on
admission and after 3, 6, 12 and 24 months.
A recurrence is defined as ultrasound- or CT-proven
acute diverticulitis after complete resolution of symp-
toms more than 1 month after initial discharge from
hospital. If a patient dies during follow-up, the reason
for death will be recorded as related or unrelated to
diverticular disease.
Randomization
Computerized block randomization for allocation of
treatment group, stratified for center and for Hinchey
1a and 1b, will take place after all inclusion and exclu-
sion criteria have been verified and informed consent
has been obtained. A standardized case record from
(CRF) will be used. This CRF is partially web-based via
a secured internet module. A minimum of 10% of the
CRF data will be verified with source data by an inde-
pendent audit.
Sample size calculation and date analysis
A non-inferiority design was chosen. Time-to-full recov-
ery in the liberal strategy arm must not exceed a clini-
cally relevant difference of more than 5 days compared
with the conservative strategy. When this condition is
fulfilled, the potential advantages of the liberal (non-
antibiotic) strategy become dominant: patient well being
when the need of hospital admission can be avoided,
less costs, less antibiotic resistance and less other side
effects. The study must have the power (superiority) to
detect a difference in time-to-full recovery of 5 days.
The median time-to-full recovery is 21 days based on
the National Dutch Hospital Registry data with an
average of 7 days admission and an assumed additional
median 14-day out-patient period to full recovery. To
reject the null-hypothesis of a difference in time-to-full
recovery of 5 days or less, using a time-to-event analysis
with a power of 85% at a confidence level of 95%, an
accrual period of 730 days and a follow-up period of
180 days, at least 264 patients need to be included in
each treatment arm. With an estimated one percent of
the trial patients lost to follow-up, a total 533 patients is
needed.
The primary endpoint is time-to-full recovery. Kaplan-
Meier curves depicting the proportion of patients with
full recovery since randomisation will be constructed for
both strategies. The log rank test will be used to test for
superiority of one strategy compared with the other.
Testing for non-inferiority will be done by calculating
the hazard ratio for the liberal strategy compared with
the conservative strategy using Cox regression. We will
calculate a one-sided 95% confidence interval for this
ratio to determine whether it reaches outside the hazard
ratio belonging to an equivalence limit of a difference of
5 days in median survival time.
For other endpoints data will be compared by the Stu-
dent’s t test, Wilcoxon rank sum test, Chi square test or
Fischer exact test as appropriate. In superiority tests a
two-tailed P value ≤ 0.05 will be considered statistically
significant, whereas one-sided tests will be performed in
non-inferiority testing. The main analyses will be based
on the intention to treat principle. Predefined subgroup
analyses to investigate whether treatment effects are dif-
ferent in subgroups will be performed for Hinchey clas-
sification 1a versus 1b and for participating center.
Cost analysis
All related costs will be estimated based on the actual
input terms of resource use and personnel in the
6-month follow-up period after randomization. For all
cost-items such as hospital admission, medication used,
diagnostic tests, unit costs will be derived from the
Table 4 Treatment strategies
Conservative strategy with antibiotics Liberal strategy without
antibiotics
- Hospital admission; - Admission only if discharge criteria
are not met;
- Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral
antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration;
- No initial antibiotics;
- Adequate pain relief (VAS < 4); - Adequate pain relief (VAS < 4);
- Oral intake as tolerated; - Oral intake as tolerated;
- Daily monitoring. - Daily monitoring when admitted to
the hospital;
-Self monitoring at home after discharge
-Out patient follow-up at regular intervals
- Self monitoring at home.
- Out patient follow-up at regular
intervals
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Dutch costing manual or determined in cooperation
with the hospital administration. Direct medical costs
will be recorded in the case record forms. Indirect costs
arising from losses in productivity will be assessed by
means of the Health and Labor questionnaire and will
be calculated by means of the friction cost method.
Economic evaluation
The economic evaluation will be performed from a soci-
etal perspective as a cost-effectiveness and cost-utility
analysis. The main analyses include costs per day reduc-
tion to achieve full recovery and costs per QALY gained.
Additional sensitivity analyses, regarding differences in
possible subgroups, will be performed.
Safety monitoring
Adverse events are defined as any undesirable experi-
ence occurring to a subject during a clinical trial,
whether or not considered related to the investigational
drug. All adverse events reported spontaneously by the
subject or observed by the investigator or his staff will
be recorded. A serious adverse event (SAE) is any unto-
ward medical occurrence or effect that at any dose
results in death; is life threatening (at the time of the
event); requires hospitalization or prolongation of exist-
ing inpatients’ hospitalization; results in persistent or
significant disability or incapacity; is a congenital anom-
aly or birth defect; is a new event of the trial likely to
affect the safety of the subjects, such as an unexpected
outcome of an adverse reaction, major safety finding
from a newly completed animal study, etc. All SAEs will
be reported to the accredited Medical Ethical Commit-
tee (MEC) that approved the protocol, according to the
requirements of that MEC.
Suspected unexpected serious adverse reactions
(SUSAR) are all untoward and unintended responses to
an investigational product related to any dose
administered.
Unexpected adverse reactions are adverse reactions, of
which the nature, or severity, is not consistent with the
applicable product information.
The sponsor will report expedited the following SUS-
ARs to the MEC; SUSARs that have arisen in the clini-
cal trial that was assessed by the MEC; SUSARs that
have arisen in other clinical trial of the same sponsor
and with the same medicinal product, and that could
have consequences for the safety of the subjects involved
in the clinical trial that was assessed by the MEC. The
remaining SUSARs are recorded in an overview list
(line-listing) that will be submitted once every half year
to the MEC. This line listing provides an overview of all
SUSARs from the study medicine, accompanied by a
brief report highlighting the main points of concern.
The sponsor will report expedited all SUSARs to the
competent authority, the Medicine Evaluation Board
and the competent authorities in other Member States.
The expedited reporting will occur not later than 15
days after the sponsor has first knowledge of the adverse
reactions. For fatal or life threatening cases the term will
be maximal 7 days for a preliminary report with another
8 days for completion of the report. There is no need to
break any code in case of a SUSAR because due to the
nature of the study in which neither participant nor
treating physician are blinded.
In addition to the expedited reporting of SUSARs, the
sponsor will submit, once a year throughout the clinical
trial, a safety report to the accredited MEC, competent
authority, Medicine Evaluation Board and competent
authorities of the concerned Member States. This safety
report consists of: a list of all suspected (unexpected or
expected) serious adverse reactions, along with an aggre-
gated summary table of all reported serious adverse
reactions, ordered by organ system, per study; a report
concerning the safety of the subjects, consisting of a
complete safety analysis and an evaluation of the bal-
ance between the efficacy and the harmfulness of the
medicine under investigation.
An independent data and safety monitoring committee
will evaluate the progress of the trial and will examine
safety parameters at regular intervals (every 25 patients).
The committee can unblind the data whenever deemed
necessary based on reported adverse events. All involved
physicians will repetitively be asked to report any poten-
tial adverse events caused by the study protocol. These
adverse events will be listed and discussed with the
monitoring committee. The monitoring committee can
ask for a full report in order to discuss a specific adverse
event. A copy of this report will be send to the central
ethics board and to the involved physicians. All
deceased patients will be evaluated by the safety com-
mittee for cause of death and possible trial related ser-
ious adverse effects. Every death will be reported to the
central ethics board and the local ethics board. The
Data Safety Monitoring Board will consist of an epide-
miologist/statistician who is the chairman, an indepen-
dent surgeon and an independent radiologist.
Ethics
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki and ‘good clinical
practice’ guidelines. The Medical Ethical Committee of
the Academic Medical Center in Amsterdam has
approved the protocol. The Ethical Committees of the
participating centers is applied for local feasibility. Prior
to randomization, written informed consent will be
obtained from all patients.
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Discussion
Diverticular disease is the most common disease of the
colon being found in every 1 of 3 people over the age of
60 years. The overall prevalence of diverticular disease
during endoscopy is 27% [32]. A recent task force con-
vened by the American Gastroenterological Association
confirmed that diverticular disease is a major clinical
problem. Diverticular disease is fifth in the list of diges-
tive diseases in terms of total costs [33]. Hospital admis-
sion rates for colonic diverticulitis have increased in the
last decades. In the United States the population-
adjusted numbers of domestic admissions for acute
diverticulitis increased by 26% [34].
Over the last decade there have been efforts made to
minimize the prescription of antibiotics in various fields in
clinical medicine. Patients with appendiceal inflammatory
masses or acute cholecystitis are not treated primarily by
antibiotics. This is also true for community-acquired infec-
tions, such as acute otitis media, upper respiratory tract
infections and in paediatric medicine [35]. Bacterial resis-
tance to antibiotics is a major public-health problem and
antibiotic use is being increasingly recognized as the main
selective pressure driving this resistance [36,37]. Develop-
ment of Clostridium-associated diarrhea is however one of
the downsides of antibiotic use, and subject of this study.
With the use of beta-lactam antibiotics, infection with
Clostridium difficile is a potential problem for all hospita-
lized patients. Clostridium difficile is implicated in 20-30%
of patients with antibiotic-associated diarrhea, in 50-70% of
those with antibiotic-associated colitis and in more than
90% of those with antibiotic-associated pseudomembranous
colitis [38]. Alternatively, there is no evidence or guideline
dictating that support anti-anaerobic prophylaxis for hospi-
talized patients in general. Prophylactic metronidazol to
prevent Clostridium-associated diarrhea is not standard
practice and is therefore not considered for this trial.
There are some new treatment options for sympto-
matic diverticular disease under investigation, such as
mesalazin and probiotics. For the present randomized
trial these treatments were not considered a reasonable
alternative. First, these treatment options are not yet
widely used and are only applied in the context of clini-
cal trials. These studies have dealt with the treatment of
uncomplicated symptomatic diverticular disease, and not
with acute diverticulitis. Patients with proven diverticu-
losis and at least one months of symptoms had been
included. These trials have excluded diverticulitis
patients [39,40]. Some studies have assessed meselazin
in the prevention of recurrent diverticulitis but never as
the actual treatment of acute diverticulitis itself [41,42].
Third and foremost, the main topic in daily practice is
whether antibiotics are mandatory in the treatment of
acute diverticulitis. Until now, no randomized controlled
trial has investigated this matter. Before other treatment
options become an issue, first the efficacy of antibiotics
in diverticulitis needs to be investigated, as this is cur-
rently standard practice in many countries.
In the present study we chose for a more pragmatic
approach to investigate the effect of antibiotics in the
treatment of acute uncomplicated diverticulitis. A clini-
cal randomized trial setting was chosen over a double-
blind placebo controlled randomized trial. Our intention
is to compare the contemporary treatment strategies in
uncomplicated acute diverticulitis. In a pragmatic trial
set-up the two possible treatment strategies can be
investigated and the outcome will be more applicable in
daily practice. In a double-blind placebo controlled trial
the effect of antibiotics will be investigated in a more
experimental setting were all patients will be admitted
and the result will not be applicable to daily practice.
Not all patients with acute diverticulitis have to be
admitted to the hospital. In 2005, Mizuki et al showed
that outpatient treatment of patients with mild or
uncomplicated diverticulitis is safe [43]. For this reason,
in the present trial hospital admission is not mandatory
in the liberal strategy arm when patients fulfill the ‘dis-
charge’ criteria at time of study entry. Part of the con-
servative treatment is hospital admission and
intravenous antibiotics as this is common practice. In
both arms the same strict criteria for discharge apply.
We decided not to stratify for age, based on the preva-
lence of diverticulitis in the different age groups and on
the latest literature on the outcome of diverticulitis.
Diverticulitis occurs in 5-10% by the age of 40 years, in
10-30% by 50 years and in more than 60% by age 80.
Recently, Hjern et al reviewed 234 patients with CT-con-
firmed diverticulitis. The rate of severe diverticulitis
observed with CT was lower in the younger patients (2%
versus 11.9%; P = 0.025). Surgical management during
the first admission was similar in younger patients (2%
versus 6.8%; P = 0.271); first episodes of acute diverticuli-
tis being not more aggressive in younger patients [13].
Variables ‘severity of disease’ (Hinchey 1a (inflammation)
versus 1b (plus micro abscesses)) and ‘participating and
including hospital’ were deemed most important with
respect to outcome and therefore in need of stratification.
Stratification for more than two variables is highly
uncommon in randomized control trials.
Right-sided diverticulitis is excluded because of uncer-
tainty about the underlying factors that contribute to
right-sided diverticulitis. In literature, a clear distinction
is made between left and right-sided diverticulitis. In
Western countries, diverticulitis mostly affects the left
colon and the incidence of right-sided diverticulitis is
estimated to be below 4%. However, in Asia and coun-
tries with a high Asian population, diverticular disease
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of the cecum and the ascending colon is a more wide-
spread disease than the left-sided form of this disease.
Sugihara et al reported on 615 Japanese patients with
diverticular disease of the colon: 69.8% with right-sided
and 15.9% with left-sided and 14.3% both-sided diverti-
cular disease [44]. Left-sided diverticular disease is
mainly based on pseudodiverticulae. The pathogenesis is
based on a higher intraluminal pressure with consecu-
tive hypertrophy of the colonic wall. In contrast, right-
sided diverticulosis, typically is associated with normal
intraluminal pressures and a tendency for bleeding
rather than perforation, presumably owing to underlying
connective tissue abnormality [45]. For the reason of
uniformity of study population only left-sided diverticu-
litis will be included.
Conclusion
The DIABOLO trial is a multicenter randomized prag-
matic trial (trialregister: NL29615.018.09, Clinicaltrial.
gov: NCT01111253) comparing the cost-effectiveness of
a conservative strategy (with admission and antibiotics)
with a liberal treatment strategy (without antibiotics and
no strict need for hospital admission) with respect to
the primary endpoint time-to-full recovery.
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